Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The transcriptomic landscape of elderly acute myeloid lekiemia identifies B7H3 and BANP as a new favorable signature in high-risk patients

ABSTRACT: Acute myeloid leukemia (AML) in the elderly remains a clinical challenge, with a five-year overall survival less than 10%. The current ELN 2017 genetic risk classification considers cytogenetic and mutational characteristics to stratify fit AML patients into different prognostic groups. However, this classification is not validated for elderly patients treated with a non-intensive approach, and its performance seems to be suboptimal in this context. Indeed, the transcriptomic landscape of AML in the elderly has been less explored and it might help stratify this group of patients. In the current study, we analyzed the transcriptome of 224 AML patients > 65 years-old at diagnosis treated in the Spanish PETHEMA-FLUGAZA clinical trial and tried to define new prognostic groups in this population. We identified a specific transcriptomic signature for high-risk patients with mutated p53 or complex karyotype, revealing that low expression of B7H3 gene with high expression of BANP gene distinguish a subset of AML patients surviving more than 12 months. This specific signature highlights the potential of transcriptomics to identify biomarkers of good prognosis in elderly AML and recognizes these two genes as possible therapeutic targets in this malignancy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE208218 | GEO | 2022/11/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The transcriptomic landscape of elderly acute myeloid lekiemia identifies B7H3 and BANP as a new favorable signature in high-risk patients

Project description:The transcriptomic landscape of elderly acute myeloid lekiemia identifies B7H3 and BANP as a new favorable signature in high-risk patients

| PRJNA858803 | ENA

BANP opens chromatin and activates CpG island regulated genes [RNA-Seq]

Project description:In mammalian genomes, the vast majority of RNA polymerase II initiation events take place at CpG island promoters. Despite their relevance our understanding of their regulation remains limited. Here we identify Banp as the long sought-after TF that binds the orphan CGCG element in CpG islands by combining single-molecule footprinting with interaction proteomics. We show that Banp drives activity of CpG islands that control essential metabolic genes in the mouse and human genome. Banp binding is strongly repelled by DNA methylation of its motif in vitro and in vivo, which restricts most binding to CpG islands and accounts for its absence at aberrantly methylated CpG islands in cancer cells. Upon binding to an unmethylated motif, Banp opens chromatin and positions nucleosomes. These findings expand our understanding of CpG island gene regulation and put forth a model whereby CpG islands rely for their activity on methylation sensitive TFs capable of opening and organizing chromatin.

2021-05-17 | GSE155664 | GEO

BANP opens chromatin and activates CpG island regulated genes [ATAC-Seq]

2021-05-17 | GSE155601 | GEO

BANP opens chromatin and activates CpG island regulated genes [MNase-seq]

2021-05-17 | GSE155600 | GEO

BANP opens chromatin and activates CpG island regulated genes [SLAM-Seq]

2021-05-17 | GSE155598 | GEO

BANP opens chromatin and activates CpG island regulated genes [ChIP-Seq]

2021-05-17 | GSE155603 | GEO

BANP is an essential transcription factor that opens chromatin and activates CpG island regulated genes

Project description:While the majority of RNA polymerase II initiation events in mammalian genomes take place within CpG island (CGI) promoters, our understanding of their regulation remains limited. Here we combine single-molecule footprinting with interaction proteomics to identify BANP as a critical CGI regulator and the long sought-after TF that binds the orphan CGCG element in mouse and human. We show that BANP drives the activity of essential metabolic genes in the mouse genome in pluripotent and terminally differentiated cells. However, BANP binding is strongly repelled by DNA methylation of its motif in vitro and in vivo, which epigenetically restricts most binding to CGIs and accounts for its absence at aberrantly methylated CGIs in cancer cells. Upon binding to an unmethylated motif, BANP opens chromatin and phases nucleosomes. Our results establish Banp as a critical activator and put forth a model whereby CGI promoter activity relies on methylation-sensitive TFs capable of chromatin opening.

2021-06-16 | PXD024794 | Pride

Multilineage dysplasia and AML with mutated nucleophosmin

Project description:Multilineage dysplasia (MLD) has no impact on biological, clinico-pathological and prognostic features of AML with mutated nucleophosmin (NPM1) NPM1-mutated AML is a provisional entity in the WHO-2008 classification of myeloid neoplasms. The significance of concomitant multilineage dysplasia (MLD) in NPM1-mutated AML is unclear. Thus, in the WHO-2008 classification, NPM1-mutated AML with MLD is classified as AML with myelodysplasia(MD)-related changes. We evaluated the MLD impact in 378 NPM1-mutated AML patients. MLD was found in about 25% cases. Except for a lower WBC and FLT3-ITD incidence in MLD+ group, no significant differences were observed in age, sex, cytogenetics and FLT3-TKD between NPM1-mutated AML with and without MLD. Notably, NPM1-mutated AML with/without MLD showed overlapping immunophenotype (CD34-negativity) and GEP (CD34 downregulation and HOX genes upregulation). Moreover, OS and EFS did not differ among NPM1-mutated AML patients, independently of whether they carried or not MLD, the NPM1-mutated/FLT3-ITD negative cases showing the better prognosis. Lack of MLD impact on survival was confirmed by multivariate analysis that highlighted FLT3-ITD as the most significant prognostic parameter in NPM1-mutated AML. Our findings indicate that NPM1 mutations rather than MLD dictate the distinctive features of NPM1-mutated AML. Thus, irrespective of MLD, NPM1-mutated AML should be considered as one disease entity clearly distinct from AML with MD-related changes. These findings have important diagnostic and prognostic implications in AML. All bone marrow samples were obtained from untreated patients at the time of diagnosis. Cells used for microarray analysis were collected from the purified fraction of mononuclear cells after Ficoll density centrifugation. 48 samples

2010-07-30 | E-GEOD-18018 | biostudies-arrayexpress

Multilineage dysplasia and AML with mutated nucleophosmin

2010-07-01 | GSE18018 | GEO

An integrative multiparametric approach stratifies distinct phenotypes of blast phase chronic myelomonocytic leukemia with differential maturation status and drug sensitivity profiles

Project description:Approximately 30% of chronic myelomonocytic leukemia patients undergo transformation to a chemo-refractory blastic phase (BP-CMML). Seeking novel therapeutic approaches we profiled blast transcriptomes from 42 BP-CMMLs, observing extensive transcriptional heterogeneity and poor alignment to current AML classifications. BP-CMMLs displayed distinctive transcriptomic profiles, including enrichment for quiescence and variability in drug response signatures. Integrating clinical, immunophenotype and transcriptome parameters, RandomForest unsupervised clustering distinguished immature and mature subtypes characterized by differential expression of transcriptional modules, oncogenes, apoptotic regulators and patterns of surface marker expression. Subtypes differed in predicted response to AML drugs, validated ex vivo in primary samples. Iteratively refined stratification resolved a classification structure comprising five subtypes along a maturation spectrum, predictive of response to novel agents including consistent patterns for RTK, CDK, MTOR and MAPK inhibitors. Finally, we generated a clinically-applicable decision tree to stratify BP-CMML with high specificity and sensitivity, and potentially guide personalized drug selection for improved outcomes.

2024-12-20 | GSE251806 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data